Skip to main content
Top
Published in: BMC Gastroenterology 1/2018

Open Access 01-12-2018 | Case report

Suspected drug-induced liver injury associated with iguratimod: a case report and review of the literature

Authors: Xiao-li Li, Xiao-Chang Liu, Yu-Lin Song, Ru-Tao Hong, Hai Shi

Published in: BMC Gastroenterology | Issue 1/2018

Login to get access

Abstract

Background

Iguratimod is a novel anti-rheumatic drug with the capability of anti-cytokines as report goes. It has been reported that iguratimod is effective and safe for rheumatoid arthritis and other rheumatisms. As side effects, iguratimod can cause gastrointestinal reactions, dizziness, headache and itchy.

Case presentation

In this case report, a 60-year-old female patient was admitted with suspected drug-induced liver injury (DILI) caused by iguratimod. The causality assessment was done by the updated RUCAM, and the possibility of the case in our paper diagnosed as highly probable for the score was 9 points. Iguratimod was discontinued immediately, and methylprednisolone was used for acute liver injury and Sjogren’s syndrome. The data showed the patient has improved gradually, and she was discharged on day 27. The true incidence of iguratimod-related hepatotoxicity and its pathogenic mechanism are largely unknown. It is difficult to recognize and diagnose DILI, and there is no standard for diagnosis of DILI. At the same time, the DILI is still lack of specific treatment.

Conclusions

Based on this rare case of severe liver injury, we recommend careful monitoring of liver function throughout iguratimod treatment for diseases.
Literature
1.
go back to reference BjORnsson ES, Bergmann OM, BjORnsson HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland [J]. Gastroenterology. 2013;144(7):19–20.CrossRef BjORnsson ES, Bergmann OM, BjORnsson HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland [J]. Gastroenterology. 2013;144(7):19–20.CrossRef
2.
go back to reference Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol. 2014;109(7):950–66.CrossRefPubMed Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol. 2014;109(7):950–66.CrossRefPubMed
3.
go back to reference Li L, Jiang W, Wang J. Clinical analysis of 275 cases of acute drug-induced liver disease [J]. Front Med. 2007;1(1):58–61.CrossRef Li L, Jiang W, Wang J. Clinical analysis of 275 cases of acute drug-induced liver disease [J]. Front Med. 2007;1(1):58–61.CrossRef
4.
go back to reference Wang Y, Zhao LF. An analysis of 66 cases of drug-induced liver injury. Zhonghua Gan Zang Bing Za Zhi. 2010;18:715–6.PubMed Wang Y, Zhao LF. An analysis of 66 cases of drug-induced liver injury. Zhonghua Gan Zang Bing Za Zhi. 2010;18:715–6.PubMed
5.
go back to reference Tanaka E, Yamanaka H. DMARDs (disease-modifying antirheumatic drugs) [J]. Nihon Rinsho Japanese. J Clin Med. 2013;71(7):1199. Tanaka E, Yamanaka H. DMARDs (disease-modifying antirheumatic drugs) [J]. Nihon Rinsho Japanese. J Clin Med. 2013;71(7):1199.
6.
go back to reference Mimori T, Harigai M, Atsumi T, et al. Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in Japan. Mod Rheumatol. 2017;27:755–65.CrossRefPubMed Mimori T, Harigai M, Atsumi T, et al. Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in Japan. Mod Rheumatol. 2017;27:755–65.CrossRefPubMed
7.
go back to reference Hara M, Abe T, Sugawara S, et al. Long-term safety study of iguratimod in patients with rheumatoid arthritis [J]. Mod Rheumatol. 2007;17(1):10–6.CrossRefPubMed Hara M, Abe T, Sugawara S, et al. Long-term safety study of iguratimod in patients with rheumatoid arthritis [J]. Mod Rheumatol. 2007;17(1):10–6.CrossRefPubMed
8.
go back to reference Hayashi PH, Fontana RJ. Clinical features, diagnosis, and natural history of drug-induced liver injury [J]. Semin Liver Dis. 2014;34(2):134–44.CrossRefPubMed Hayashi PH, Fontana RJ. Clinical features, diagnosis, and natural history of drug-induced liver injury [J]. Semin Liver Dis. 2014;34(2):134–44.CrossRefPubMed
9.
go back to reference Licata A, Minissale MG. Calvaruso V.A focus on epidemiology of drug-induced liver injury: analysis of a prospective cohort. Eur Rev Med Pharmacol Sci. 2017;21:112–21.PubMed Licata A, Minissale MG. Calvaruso V.A focus on epidemiology of drug-induced liver injury: analysis of a prospective cohort. Eur Rev Med Pharmacol Sci. 2017;21:112–21.PubMed
10.
go back to reference Robles-Diaz M, Lucena MI, Kaplowitz N, et al. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury [J]. Gastroenterology. 2014;147(1):109.CrossRefPubMed Robles-Diaz M, Lucena MI, Kaplowitz N, et al. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury [J]. Gastroenterology. 2014;147(1):109.CrossRefPubMed
12.
go back to reference Rolf T, Albrecht, et al. Drug and herb induced liver injury: Council for International Organizations of medical sciences scale for causality assessment [J]. World J Hepatol. 2014;6(1):17.CrossRef Rolf T, Albrecht, et al. Drug and herb induced liver injury: Council for International Organizations of medical sciences scale for causality assessment [J]. World J Hepatol. 2014;6(1):17.CrossRef
13.
go back to reference Yi LI, Peng M, Gong G. Evaluation of the revised versus the simplified scoring system in patients with autoimmune hepatitis [J]. Exp Ther Med. 2014;7(1):131–6.CrossRef Yi LI, Peng M, Gong G. Evaluation of the revised versus the simplified scoring system in patients with autoimmune hepatitis [J]. Exp Ther Med. 2014;7(1):131–6.CrossRef
14.
go back to reference Lucena MI, Andrade RJ, Kaplowitz N, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex [J]. Hepatology. 2009;49(6):2001–9. Lucena MI, Andrade RJ, Kaplowitz N, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex [J]. Hepatology. 2009;49(6):2001–9.
15.
go back to reference Tanaka K, Yamaguchi T, Hara M. Iguratimod for the treatment of rheumatoid arthritis in Japan.[J]. Expert Rev Clin Immunol. 2015;11(5):1–9.CrossRef Tanaka K, Yamaguchi T, Hara M. Iguratimod for the treatment of rheumatoid arthritis in Japan.[J]. Expert Rev Clin Immunol. 2015;11(5):1–9.CrossRef
16.
go back to reference Du F, Lü LJ, Fu Q, et al. T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis [J]. Arthritis Res Ther. 2008;10(6):R136.CrossRefPubMedPubMedCentral Du F, Lü LJ, Fu Q, et al. T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis [J]. Arthritis Res Ther. 2008;10(6):R136.CrossRefPubMedPubMedCentral
17.
go back to reference Wei Y, Sun X, Hua M, et al. Inhibitory effect of a novel Antirheumatic drug T-614 on the IL-6-induced RANKL/OPG, IL-17, and MMP-3 expression in synovial fibroblasts from rheumatoid arthritis patients. Biomed Res Int. 2015;2015(4):214683.PubMedPubMedCentral Wei Y, Sun X, Hua M, et al. Inhibitory effect of a novel Antirheumatic drug T-614 on the IL-6-induced RANKL/OPG, IL-17, and MMP-3 expression in synovial fibroblasts from rheumatoid arthritis patients. Biomed Res Int. 2015;2015(4):214683.PubMedPubMedCentral
18.
go back to reference Sawada T, Hashimoto S, Tohma S, et al. Inhibition of L-leucine methyl ester mediated killing of THP-1, a human monocytic cell line, by a new anti-inflammatory drug, T614 [J]. Immunopharmacology. 2000;49(3):285–94.CrossRefPubMed Sawada T, Hashimoto S, Tohma S, et al. Inhibition of L-leucine methyl ester mediated killing of THP-1, a human monocytic cell line, by a new anti-inflammatory drug, T614 [J]. Immunopharmacology. 2000;49(3):285–94.CrossRefPubMed
20.
go back to reference Mao YM, Zeng MD, Chen Y, et al. Magnesium isoglycyrrhizinate in the treatment of chronic liver diseases: a randomized, double-blind, multi-doses, active drug controlled, multi-center study [J]. Chin J Hepatol. 2009;17(11):847. Mao YM, Zeng MD, Chen Y, et al. Magnesium isoglycyrrhizinate in the treatment of chronic liver diseases: a randomized, double-blind, multi-doses, active drug controlled, multi-center study [J]. Chin J Hepatol. 2009;17(11):847.
21.
go back to reference Zhao P, Duan G, Li DU, et al. Systematic evaluation on the efficacy of ademetionine in patients with drug-induced liver injury [J]. Chinese J Gastroenterology Hepatology. 2011;95(6):3212–7. Zhao P, Duan G, Li DU, et al. Systematic evaluation on the efficacy of ademetionine in patients with drug-induced liver injury [J]. Chinese J Gastroenterology Hepatology. 2011;95(6):3212–7.
22.
go back to reference Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144:1419–25.CrossRefPubMed Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144:1419–25.CrossRefPubMed
Metadata
Title
Suspected drug-induced liver injury associated with iguratimod: a case report and review of the literature
Authors
Xiao-li Li
Xiao-Chang Liu
Yu-Lin Song
Ru-Tao Hong
Hai Shi
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2018
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-018-0858-z

Other articles of this Issue 1/2018

BMC Gastroenterology 1/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.